Related Experiment Video

Updated: May 26, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro

You Qin1, Chun-Yan Sun, Fu-Rong Lu

  • 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.

Leukemia Research
|January 10, 2012
PubMed

Insights

Cardamonin, a natural compound, effectively reduces multiple myeloma cell growth and triggers cell death by inhibiting the NF-κB pathway. This study reveals cardamonin

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Nuclear factor-kappa B (NF-κB) is a key regulator in multiple myeloma pathogenesis.
  • Understanding novel therapeutic targets for multiple myeloma is crucial.

Purpose of the Study:

  • To investigate the effect of cardamonin on NF-κB signaling in multiple myeloma cells.
  • To explore cardamonin's potential as a therapeutic agent against multiple myeloma.

Main Methods:

  • Cell viability assays were performed to assess cardamonin's effect on myeloma cell proliferation.
  • Apoptosis was evaluated by measuring caspase-3 and PARP activation.
  • Western blotting was used to analyze protein expression, including IKK, IκBα, and NF-κB-regulated proteins (ICAM-1, COX-2, VEGF).

Main Results:

  • Cardamonin significantly suppressed myeloma cell viability and induced apoptosis.
  • Cardamonin activated pro-apoptotic proteins (caspase-3, PARP) and reduced anti-apoptotic proteins.
  • Cardamonin repressed NF-κB activation by inhibiting IKK expression and IκBα phosphorylation.
  • Down-regulation of NF-κB target genes (ICAM-1, COX-2, VEGF) was observed.

Conclusions:

  • Cardamonin effectively inhibits the NF-κB pathway in human multiple myeloma cells.
  • Cardamonin demonstrates potential as a therapeutic agent for multiple myeloma by targeting the NF-κB pathway.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...